ACC 2018 | COMBO: New Stent with Thin Struts and Pro-Healing Membrane

The new COMBO stent, comprised of thin struts plus a bioengineered layer of endothelial progenitor cells, is safe and effective at 1 year, according to this registry (the largest study on this device to date).

This new stent could provide a better option for patients at high risk for bleeding who may not be able to use long-term dual antiplatelet therapy.

At 1 year, the primary endpoint (a composite of cardiac death, target-vessel infarction and clinically-driven revascularization) was 3.9%. Upon individual consideration, cardiac death was 1.6%, target-vessel infarction was 1.2%, and clinically-driven revascularization was 2.2%. Definite/probable stent thrombosis was 0.8% at 1 year.

Read also: Transulnar Access: Another Ace Up Our Sleeve Before Transfemoral Access.

Such encouraging results seem to warrant a comparative study against a newer-generation drug-eluting stent.

Original title: One-Year Clinical Outcomes of the Bio-Engineered Combo Stent: Primary Results from the 3614 All-Comer Patients in the COMBO Collaboration.

Presenter: Colombo A.

¿Le gustaría recibir un resumen semanal con los más recientes artículos científicos?

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.